# Johnson & Johnson (JNJ) — Q4-2018 Earnings Results

**Report date:** 2019-01-22 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/JNJ/earnings/Q4-2018

## Post-Earnings Brief

### Headline

Johnson & Johnson Beats on EPS, Stock Down N/A

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.02 | N/A | +2.57% |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in their pharmaceutical pipeline while acknowledging some headwinds in consumer health. They emphasized their commitment to long-term growth.

**Key quotes:**

> Management highlighted ongoing strength in their pharmaceutical segment.

> They noted challenges in consumer health products but remain focused on innovation.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

This earnings report shows that Johnson & Johnson was able to exceed earnings expectations, particularly driven by their pharmaceutical division. However, the lack of revenue data and guidance may leave investors uncertain about future performance. The stock reaction is not available, but the earnings beat could indicate positive momentum in the company's core areas.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/JNJ/earnings/Q4-2018_